Catalyst Biosciences (Catalyst Biosciences) GF Value : $0.13 (As of May. 11, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Catalyst Biosciences GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-11), Catalyst Biosciences's share price is $7.669499. Catalyst Biosciences's GF Value is $0.13. Therefore, Catalyst Biosciences's Price-to-GF-Value for today is 59.00.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Catalyst Biosciences is Data Out of Date, Use Caution.

Catalyst Biosciences (NAS:CBIO) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Catalyst Biosciences's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	7.669499	/	0.13
	=	59.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Biosciences GF Value Related Terms

Thank you for viewing the detailed overview of Catalyst Biosciences's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Biosciences (Catalyst Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Biosciences Inc (NAS:CBIO) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 710, South San Francisco, CA, USA, 94080

Website

https://www.catalystbiosciences.com

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

Executives

Han Ying	director	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Charles C Wu	director, officer: Chief Executive Officer	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Songjiang Ma	director, officer: President	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Weiguo Ye	officer: Chief Operating Officer	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Renate Parry	director	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ruoyu Chen	officer: Interim CFO	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gordon Carmichael	director	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gni Usa, Inc.	10 percent owner	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Augustine Lawlor	director	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Andrea Hunt	director	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Seline E. Miller	officer: SVP Finance; Interim CFO & PAO	C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Gni Hong Kong Ltd	10 percent owner	12/F ELITE CENTRE, 22 HUNG TO ROAD, KWUN TONG KL K3 0000
Gni Group Ltd.	10 percent owner	NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023
Thomas Wilson Eastling	director	17520 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ying Luo	director	NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023